このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Optomed Oyj マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Juho Himberg

最高経営責任者

€64.0k

報酬総額

CEO給与比率	81.3%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	5.5yrs
取締役会の平均在任期間	3.5yrs

経営陣の近況

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

May 11

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

May 10

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Mar 22

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Dec 21

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Nov 15

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Aug 09

The Optomed Oyj (HEL:OPTOMED) Share Price Has Gained 14% And Shareholders Are Hoping For More

Feb 16

CEO報酬分析

Optomed Oyj の収益と比較して、Juho Himberg の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-€4m
Dec 31 2023	€64k	€52k	-€4m

報酬と市場: Juhoの総報酬 ($USD 68.72K ) は、 Finnish市場 ($USD 330.49K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Juhoの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Juho Himberg (54 yo)

less than a year

在職期間

€64,000

報酬

Mr. Juho Himberg is Chief Executive Officer of Optomed Oyj since October 1, 2023. He has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Juho Himberg	Chief Executive Officer	less than a year	€64.00k	データなし
Seppo Kopsala	Founder	20.5yrs	€156.00k	データなし
Sakari Knuutti	CFO, Chief Legal Officer & Secretary of the Board	5.5yrs	データなし	データなし

5.5yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: OPTOMEDの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Seppo Makinen	Independent Director	5.5yrs	€19.00k	0.057% € 63.9k
Reijo Tauriainen	Independent Director	5.5yrs	€19.00k	0.073% € 81.9k
Catherine Calarco	Independent Director	1.2yrs	€19.00k	0.011% € 12.6k
Petri Salonen	Chairman of the Board	18.5yrs	€114.00k	0.071% € 79.9k
Ty Lee	Independent Director	1.2yrs	€19.00k	0.011% € 12.6k
Anna Tenstam	Independent Director	4.1yrs	€19.00k	0.031% € 34.7k
Robert Chang	Member of International Scientific Advisory Board	3.5yrs	データなし	データなし
Nina Hautala	Member of International Scientific Advisory Board	3.5yrs	データなし	データなし
Dan Milea	Member of International Scientific Advisory Board	3.5yrs	データなし	データなし
Tunde Peto	Member of International Scientific Advisory Board	3.5yrs	データなし	データなし
Daniel Ting	Member of International Scientific Advisory Board	3.5yrs	データなし	データなし

3.5yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: OPTOMEDの取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Optomed Oyj マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Optomed Oyj Announces Nomination Board

Optomed Oyj, Annual General Meeting, May 10, 2024

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

High number of new and inexperienced directors

Recent updates

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

Price target increased by 14% to €6.63

Forecast to breakeven in 2026

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

First quarter 2024 earnings released: €0.064 loss per share (vs €0.076 loss in 1Q 2023)

New major risk - Share price stability

Optomed Plc Announces Optomed Aurora with AEYE Receives U.S. Food & Drug Administration Clearance in US

Optomed USA, Inc. Introduces Optomed Aurora AEYE

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Consensus estimates of losses per share improve by 15%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 12%

Consensus revenue estimates decrease by 12%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Optomed Oyj Announces Nomination Board

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optomed Oyj Provides Revenue Guidance for the Year 2023

Forecast breakeven date moved forward to 2024

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.290413 million.

Consensus EPS estimates fall by 15%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

New major risk - Share price stability

Optomed Oyj, Annual General Meeting, May 10, 2024

Forecast breakeven date pushed back to 2025

Optomed Announces CEO Transition Plan

Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Optomed Oyj Approves Board Changes

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Optomed Plc Provides Revenue Guidance for the Full Year 2023

Price target decreased by 9.9% to €6.37

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS misses analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year of 2023

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Consensus EPS estimates fall by 12%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Updates Earnings Guidance for the Full Year 2022

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Optomed Oyj Announces Board Appointments

Optomed plc Elects Mars Duan to the Board of Directors

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Optomed Oyj, Annual General Meeting, May 10, 2023

Optomed Plc Announces Resignation of Xisi Guo from Board of Directors, Effective August 19, 2022

Optomed Oyj Announces Resignation of Niina Huikuri as Vice President, Marketing and Member of the Leadership Team

Optomed Oyj Announces Executive Changes

Optomed Oyj Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.822593 million.

Price target decreased to €8.45

No longer forecast to breakeven

High number of new and inexperienced directors

Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

No longer forecast to breakeven

Price target decreased to €9.95

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj Provides Revenue Guidance for the Year 2022

Optomed Oyj Announces Correction in Clinical Trial Results

Optomed Oyj to Report Fiscal Year 2021 Results on Mar 04, 2022

Optomed Announces Promising Research Results with Aurora Handheld Fundus Camera

Forecast to breakeven in 2024

Third quarter 2021 earnings released: €0.062 loss per share (vs €0.031 loss in 3Q 2020)

Price target decreased to €12.70

Second quarter 2021 earnings released: €0.065 loss per share (vs €0.083 loss in 2Q 2020)

マネジメント基準チェック /34